HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

D-Dimer and thrombus burden in acute pulmonary embolism.

AbstractBACKGROUND:
Thrombus burden in pulmonary embolism (PE) is associated with higher D-Dimer-levels and poorer prognosis. We aimed to investigate i) the influence of right ventricular dysfunction (RVD), deep venous thrombosis (DVT), and high-risk PE-status on D-Dimer-levels and ii) effectiveness of D-Dimer to predict RVD in normotensive PE patients.
METHODS:
Overall, 161 PE patients were analyzed retrospectively, classified in 5 subgroups of thrombus burden according to clinical indications and compared regarding D-Dimer-levels. Linear regression models were computed to investigate the association between D-Dimer and the groups. In hemodynamically stable PE patients, a ROC curve was calculated to assess the effectiveness of D-Dimer for predicting RVD.
RESULTS:
Overall, 161 patients (60.9% females, 54.0% aged >70 years) were included in this analysis. The D-Dimer-level was associated with group-category in a univariate linear regression model (β 0.050 (95%CI 0.002-0.099), P = .043). After adjustment for age, sex, cancer, and pneumonia in a multivariate model we observed an association between D-Dimer and group-category with borderline significance (β 0.047 (95%CI 0.002-0.096), P = .058). The Kruskal-Wallis test demonstrated that D-Dimer increased significantly with higher group-category. In 129 normotensive patients, patients with RVD had significantly higher D-Dimer values compared to those without (1.73 (1.11/3.48) vs 1.17 (0.65/2.90) mg/l, P = .049). A ROC curve showed an AUC of 0.61, gender non-specific, with calculated optimal cut-off of 1.18 mg/l. Multi-variate logistic regression model confirmed an association between D-Dimer >1.18 mg/l and RVD (OR2.721 (95%CI 1.196-6.190), P = .017).
CONCLUSIONS:
Thrombus burden in PE is related to elevated D-Dimer levels, and D-Dimer values >1.18 mg/l were predictive for RVD in normotensive patients. D-Dimer levels were influenced by DVT, but not by cancer, pneumonia, age, or renal impairment.
AuthorsKarsten Keller, Johannes Beule, Jörn Oliver Balzer, Wolfgang Dippold
JournalThe American journal of emergency medicine (Am J Emerg Med) Vol. 36 Issue 9 Pg. 1613-1618 (09 2018) ISSN: 1532-8171 [Electronic] United States
PMID29371044 (Publication Type: Journal Article)
CopyrightCopyright © 2018 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
Topics
  • Acute Disease
  • Aged
  • Biomarkers (metabolism)
  • Female
  • Fibrin Fibrinogen Degradation Products (metabolism)
  • Humans
  • Male
  • Prognosis
  • Pulmonary Embolism (blood, diagnosis)
  • ROC Curve
  • Retrospective Studies
  • Venous Thrombosis (blood, complications)
  • Ventricular Dysfunction, Right (blood, complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: